WO2004048314A1 - Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2) - Google Patents

Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2) Download PDF

Info

Publication number
WO2004048314A1
WO2004048314A1 PCT/EP2003/013246 EP0313246W WO2004048314A1 WO 2004048314 A1 WO2004048314 A1 WO 2004048314A1 EP 0313246 W EP0313246 W EP 0313246W WO 2004048314 A1 WO2004048314 A1 WO 2004048314A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
cyclopropyl
mmol
chloro
fluoro
Prior art date
Application number
PCT/EP2003/013246
Other languages
English (en)
Inventor
Roger Aki Fujimoto
Leslie Wighton Mcquire
Lauren G. Monovich
Benjamin Biro Mugrage
David Thomas Parker
John Henry Van Duzer
Sompong Wattanasin
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to EP03767652A priority Critical patent/EP1567477B1/fr
Priority to JP2004554464A priority patent/JP4580240B2/ja
Priority to AU2003292112A priority patent/AU2003292112A1/en
Priority to AT03767652T priority patent/ATE442348T1/de
Priority to BR0316615-5A priority patent/BR0316615A/pt
Priority to CA002507458A priority patent/CA2507458A1/fr
Priority to DE60329219T priority patent/DE60329219D1/de
Publication of WO2004048314A1 publication Critical patent/WO2004048314A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Definitions

  • the invention relates to phenylacetic acids and derivatives as defined herein which are particularly potent and selective cyclooxygenase-2 (COX-2) inhibitors, methods for preparation thereof, pharmaceutical compositions comprising said compounds, methods of selectively inhibiting COX-2 activity and of treating conditions in mammals which are responsive to COX-2 inhibition using said compounds or pharmaceutical compositions comprising said compounds of the invention.
  • COX-2 cyclooxygenase-2
  • the present invention provides novel phenylacetic acids and derivatives which inhibit COX-2 without significantly inhibiting cyclooxygenase- 1 (COX-1).
  • the invention thus provides novel non-steroidal anti-inflammatory agents which are surprisingly free of undesirable side effects usually associated with the classical non-steroidal anti-inflammatory agents, such as gastrointestinal and renal side effects.
  • the compounds of the present invention are thus particularly useful or may be metabolically converted to compounds which are particularly useful as selective COX-2 inhibitors. They are thus particularly useful for the treatment of COX-2 dependent disorders in mammals, including inflammation, pyresis, pain, osteoarthritis, rheumatoid arthritis, dysmenorrhea, migraine headache, cancer (such as of the digestive tract, e.g., colon cancer and melanoma), neurodegenerative diseases (such as multiple sclerosis, Parkinson's disease and Alzheimer's disease), cardiovascular disorders (such as atherosclerosis, coronary artery disease and arteriosclerosis), osteoporosis, asthma, lupus and psoriasis while substantially eliminating undesirable gastrointestinal ulceration associated with conventional cyclooxygenase (COX) inhibitors.
  • the compounds of the invention are also UV absorbers, in particular, UV-B absorbers, and are useful for blocking or absorbing UV radiation, for instance, for the treatment and prevention of sunburn, e.g., in suntan products.
  • Ocular applications of the compounds of the invention include the treatment of ocular inflammation, of ocular pain including pain associated with ocular surgery, such as PRK or cataract surgery, of ocular allergy, of photophobia of various etiology, of elevated intraocular pressure (in glaucoma) by inhibiting the production of trabecular meshwork inducible glucocorticoid response protein and of dry eye disease.
  • the compounds of the present invention are useful for the treatment of neoplasia particularly neoplasia that produce prostaglandins or express COX, including both benign and cancerous tumors, growths and polyps, in particular, epithelium cell-derived neoplasia.
  • Compounds of the present invention are, in particular, useful for the treatment of liver, bladder, pancreatic, ovarian, prostate, cervical, lung and breast cancer and, especially gastrointestinal cancer, e.g., cancer of the colon, and skin cancer, e.g., squamous cell or basal cell cancers and melanoma, as indicated above.
  • gastrointestinal cancer e.g., cancer of the colon
  • skin cancer e.g., squamous cell or basal cell cancers and melanoma, as indicated above.
  • treatment is to be understood as including both therapeutic and prophylactic modes of therapy, e.g., in relation to the treatment of neoplasia, therapy to prevent the onset of clinically or pre-clinically evident neoplasia, or for the prevention of initiation of malignant cells or to arrest or reverse the progression of pre-malignant to malignant cells, as well as the prevention or inhibition of neoplasia growth or metastasis.
  • the present invention is, in particular, to be understood as embracing the use of compounds of the present invention to inhibit or prevent development of skin cancer, e.g., squamous or basal cell carcinoma consequential to UV light exposure, e.g., resulting from chronic exposure to the sun.
  • the invention relates to compounds of formula (I)
  • R is hydrogen, lower alkyl, (C 3 -C 6 )cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted ⁇ -naphthyl, bicyclic heterocyclic aryl, (C 3 -C 6 )cycloalkyl- monocyclic carbocyclic aryl, or (C 5 or C 6 )cycloalkane fused-monocyclic carbocyclic aryl; provided that when bicyclic heterocyclic aryl is optionally substituted quinolinyl, R is located at the 5-position and R does not represent hydrogen; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • Particular embodiments of the invention relate to compounds of formula (I), wherein A represents optionally substituted ⁇ -naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted 5,6,7,8-tetrahydronaphthyl, optionally substituted indanyl, optionally substituted biphenylyl, optionally substituted (C 3 -C 6 )cycloalkyl- phenyl or optionally substituted monocyclic heteroaryl-phenyl; provided that when A is optionally substituted quinolinyl, R is located at the 5-position and R does not represent hydrogen; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • a more particular embodiment of the invention relates to the compounds of formula (II)
  • R is hydrogen, (d-C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo, lower alkoxy, trifluoromethoxy, cyano or trifluoromethyl; i s hydrogen, fluoro, chloro, (Ci or C 2 )alkyl or trifluoromethyl; R s hydrogen, fluoro, chloro, (d or C 2 )alkyl or trifluoromethyl;
  • R 3 s optionally substituted phenyl or (C 3 -C 6 )cycloalkyl
  • R 4 s hydrogen, halo, lower alkyl or trifluoromethyl
  • R 5 is halo, lower alkyl or trifluoromethyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • R is preferably located at the 5-position of the ring.
  • a more particular embodiment of the invention relates to the compounds of formula (II), wherein
  • R is hydrogen, methyl, ethyl, propyl, methoxy, chloro, fluoro, cyclopropyl, cyano, trifluoromethoxy or trifluoromethyl;
  • RL R 2 , R and R 5 are, independently, hydrogen, fluoro or chloro;
  • R 3 is (C 3 -C 6 )cycloalkyl, phenyl, or phenyl mono- or poly-substituted independently by lower alkyl, fluoro, chloro, lower alkoxy or (C ⁇ or C 2 )alkylenedioxy; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • Another particular embodiment of the invention relates to the compounds of formula (III)
  • R is hydrogen, (C C ⁇ alkyl, (C 3 -C 6 )cycloalkyl, halo, lower alkoxy, trifluoromethoxy or trifluoromethyl;
  • Ri is hydrogen, chloro, fluoro or (Ci or C 2 )alkyl
  • R 2 is hydrogen or fluoro
  • R 3 is cyclopropyl, cyclohexyl, phenyl or phenyl substituted by chloro, fluoro, lower alkoxy, lower alkyl or lower alkylenedioxy;
  • R 4 is hydrogen, (Ci or C 2 )alkyl, trifluoromethyl or fluoro;
  • R 5 is fluoro, chloro or (Ci or C 2 )alkyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • a further embodiment of the invention relates to the compounds of formula (III), wherein
  • R is (C-i or C 2 )-alkyl, cyclopropyl, chloro or fluoro; Ri is chloro or fluoro; R 2 is hydrogen or fluoro; R 3 is cyclopropyl;
  • R 4 is hydrogen, methyl or fluoro; and R 5 is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • R is hydrogen, lower alkyl, (C 3 -C 6 )cycloalkyl, halo, lower alkoxy, trifluoromethoxy, cyano or trifluoromethyl; and A is selected from radicals (a) and (b)
  • R 6 -Rs are, independently, hydrogen, lower alkyl, lower alkoxy, trifluoromethyl or halo; and wherein in radical (b)
  • R 9 -R 12 are, independently, hydrogen, lower alkyl, lower alkoxy, trifluoromethyl or halo; and X and Y are CH, or one of the X and Y is N and the other is CH; provided that when X is N and Y is CH, R is located at the 5-position and R does not represent hydrogen; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • At least one of R 6 and R 7 and one of R 9 and R 10 is lower alkyl or halo.
  • a further embodiment of the invention relates to the compounds of formula (Ilia)
  • R is lower alkyl, cyclopropyl, chloro or fluoro
  • R 9 is hydrogen, chloro or fluoro
  • R 10 is chloro or fluoro
  • R ⁇ is fluoro, chloro or lower alkoxy; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.
  • R is preferably methyl, ethyl, propyl, cyclopropyl, chloro or fluoro, most preferably chloro, methyl, ethyl or cyclopropyl.
  • esters are preferably prodrug ester derivatives which are convertible by solvolysis or under physiological conditions to the free carboxylic acids of, e.g., formula (I).
  • Such esters are, e.g., lower alkyl esters, such as the methyl or ethyl ester; carboxy-lower alkyl esters, such as the carboxymethyl ester; nitrooxy- or nitrosooxy-lower alkyl esters, such as the 4-nitrooxybutyl or 4-nitrosooxybutyl ester; and the like.
  • Preferred are the phenylacetoxyacetic acids of formula (la)
  • R and A have meaning as defined hereinabove for compounds of formulae (l)-(llla); and pharmaceutically acceptable salts thereof.
  • Pharmaceutically acceptable salts represent metal salts, such as alkaline metal salts, e.g., sodium, potassium, magnesium or calcium salts; as well as ammonium salts, which are formed, e.g., with ammonia and mono- or di-alkylamines, such as diethylammonium salts; and with amino acids, such as arginine and histidine salts.
  • a lower alkyl group contains up to 7 carbon atoms, preferably 1-4 carbon atoms, may be straight chain or branched and represents, e.g., methyl, ethyl, propyl, butyl, isopropyl, isobutyl and the like, preferably methyl or ethyl.
  • Lower alkoxy is methoxy, ethoxy and the like.
  • Biaryl represents two directly linked monocyclic aryl groups which are, independently, either carbocyclic or heterocyclic.
  • Biaryl for A in formula (I) represents monocyclic carbocyclic aryl substituted by monocyclic carbocyclic aryl, namely biphenylyl, advantageously 3- or 4-biphenylyl, optionally substituted on one or both benzene rings by one or more of lower alkyl, halo, hydroxy, lower alkoxy, trifluoromethoxy, lower alkylenedioxy and trifluoromethyl, advantageously wherein at least one substituent is ortho to the point of attachment of the NH group.
  • Biaryl also represents monocyclic carbocyclic aryl substituted by heterocyclic aryl, namely optionally substituted monocyclic heteroarylphenyl, preferably phenyl substituted in the meta- or para- position by, e.g., thiazolyl, thienyl, pyridyl, oxazolyl or isoxazolyl, in which one or both rings are optionally substituted by one or more substituents selected from lower alkyl, halo and trifluoromethyl, advantageously at least one said substituent being ortho to the point of attachment of the NH group.
  • Optionally substituted ⁇ -naphthyl for A in formula (I) is 2-naphthyl optionally substituted at one or both of the 1- and 3-positions by, e.g., halo, lower alkyl or trifluoromethyl, and further optionally substituted, e.g., at the 6- or 7-position by halo, lower alkyl, lower alkoxy, trifluoromethyl or hydroxy.
  • Bicyclic heterocyclic aryl for A in formula (I) is preferably quinolinyl or isoquinolinyl, each being optionally substituted by one or more substituents independently selected from, e.g., halo, lower alkyl, lower alkoxy and trifluoromethyl.
  • (C 3 -C 6 )Cycloalkyl-monocyclic carbocyclic aryl for A in formula (I) is phenyl substituted, preferably in the para or meta position, by (C 3 -C 6 )cycloalkyl, e.g., cyclopropyl, cyclopentyl or cyclohexyl, and further optionally substituted by one or more (1-4) substituents independently selected from, e.g., lower alkyl, lower alkoxy, halo and trifluoromethyl, advantageously at least one said substituent being ortho to the point of attachment of the NH group.
  • (C 3 -C 6 )cycloalkyl e.g., cyclopropyl, cyclopentyl or cyclohexyl
  • substituents independently selected from, e.g., lower alkyl, lower alkoxy, halo and trifluoromethyl, advantageously at least one said substituent being ortho to the point of
  • (C 3 -C 6 )CycIoalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably cyclopropyl.
  • (C 5 or C 6 )Cycloalkane fused-monocarbocyclic aryl for A in formula (I) is preferably 5-indanyl or (2- or 3-)5,6,7,8-tetrahydronaphthyl, each being optionally substituted on the benzene ring thereof by one or more substituents independently selected from, e.g., halo, lower alkyl, lower alkoxy and trifluoromethyl.
  • Monocyclic carbocyclic aryl is optionally substituted phenyl, e.g., phenyl or phenyl substituted by 1-5 substituents independently selected from, e.g., lower alkyl, halo, trifluoromethyl and lower alkoxy.
  • Monocyclic heteroaryl is 5- or 6-membered heteroaryl, which contains 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur, and represents preferably thiazolyl, thienyl, pyridyl, pyrimidinyl, oxazolyl or isoxazolyl optionally substituted by, e.g., lower alkyl or halo.
  • Halo is preferably chloro, bromo or fluoro, advantageously chloro or fluoro.
  • Optionally substituted quinolinyl is quinolinyl or quinolinyl substituted by, e.g., lower alkyl, halo, lower alkoxy or trifluoromethyl.
  • isoquinolinyl is isoquinolinyl or isoquinolinyl substituted by, e.g., lower alkyl, halo, lower alkoxy or trifluoromethyl.
  • Optionally substituted 5,6,7,8-tetrahydronaphthyl is 5,6,7,8-tetrahydronaphthyl or 5,6,7,8-tetrahydronaphthyl substituted on the phenyl ring by, e.g., lower alkyl, halo, lower alkoxy or trifluoromethyl.
  • Optionally substituted indanyl is indanyl or indanyl substituted on the phenyl ring by, e.g., lower alkyl, halo, lower alkoxy or trifluoromethyl.
  • Optionally substituted biphenylyl is preferably 3- or 4-biphenylyl or 3- or 4-biphenylyl substituted on one or both benzene rings by one or more substituents independently selected from, e.g., lower alkyl, lower alkoxy, halo and trifluoromethyl.
  • Optionally substituted (C 3 -C 6 )cycloalkylphenyl is phenyl substituted by, e.g., cyclopropyl, cyclopentyl or cyclohexyl, advantageously in the para position, in which the phenyl ring is further optionally substituted by 1-4 substituents independently selected from, e.g., lower alkyl, halo, lower alkoxy and trifluoromethyl.
  • the compounds of the invention are useful as selective COX-2 inhibitors or as prodrugs thereof.
  • the selective COX-2 inhibitors and prodrugs thereof of the invention are particularly useful for the treatment of, e.g., inflammation, pyresis, pain, osteoarthritis, dysmenorrhea, rheumatoid arthritis and other conditions responsive to the inhibition of COX-2 and are typically substantially free of undesirable gastrointestinal side effects associated with conventional non-steroidal anti-inflammatory agents.
  • the above-cited properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., rats, mice, dogs, monkeys and isolated cells or enzyme preparations of human and non-human origin.
  • Said compounds can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo advantageously orally, topically or parenterally, e.g., intravenously.
  • the dosage in vitro may range from about 10 "5 -10 "9 molar concentrations.
  • the dosage in vivo may range, depending on the route of administration, between about 1 mg/kg and 100 mg/kg.
  • COX-2 inhibition is determined in an enzymatic in vitro assay using a commercially available kit (Cayman Chemical Company).
  • test compound stock solution in DMSO diluted with buffer to various concentrations
  • 30-50 units of purified recombinant human COX-2 and hemactin (1 ⁇ M) for 30 minutes at 25°C, followed by incubation with 100 ⁇ M arachidonic acid and the colorimetric substrate TMPD (N,N,N', ⁇ '-tetramethyl-p-phenylenediamine) for 5-7 minutes at 25°C, followed by colorimetric detection of oxidized TMPD at 590 nm.
  • TMPD N,N,N', ⁇ '-tetramethyl-p-phenylenediamine
  • COX inhibition is also determined in vitro using cellular assays for inhibition of both COX-1 and COX-2.
  • COX enzyme prostaglandin H synthase catalyzes the rate limiting step in prostaglandin synthesis from arachidonic acid.
  • COX-1 is a constitutive form of the enzyme whereas COX-2 is induced in response to various growth factors and cytokines.
  • In vitro COX-1 and COX-2 inhibition is determined in the cell-based assays in order to assess the in vitro activity and selectivity for COX-2 inhibition, using a prostaglandin E 2 immunoassay (Cayman PGE 2 Kit).
  • the cells utilized are HEK-293 EBNA cells that have been transfected and have a stable expression of either recombinant human COX-1 or recombinant human COX-2, respectively.
  • Cells are plated out into 96-well plates in which the assay is performed. Both cell lines are pre-treated with compound dilutions for 30 minutes at 37°C, then arachidonic acid (1 ⁇ M) is added as exogenous substrate.
  • the supernatant is harvested 15 minutes later and the production of PGE 2 is measured by immunoassay.
  • compounds are tested at 5-9 concentrations in singlet, duplicate or quadruplicate replicates at each concentration (highest concentration 30 ⁇ M).
  • the mean inhibition of PGE 2 (compared to cells not treated with compound) for each concentration is calculated, a plot is made of mean % inhibition versus log compound concentration, and the IC 50 value calculated using a 4-parameter logistic fit. The relative effects on each enzyme are compared to assess selectivity for inhibition of COX-2.
  • COX-1 and COX-2 inhibition are also determined in human whole blood where COX-1 is constitutively expressed in platelets and COX-2 expression is induced in mononuclear cells by treatment with lipopolysaccharide (LPS) (10 ⁇ g/mL).
  • LPS lipopolysaccharide
  • heparinized human blood is divided into two aliquots: one for measuring TxB 2 production (a surrogate indicator of COX-1 activity) and a second for measuring PGE 2 production (a surrogate for COX-2 activity).
  • TxB 2 production a surrogate indicator of COX-1 activity
  • PGE 2 production a surrogate for COX-2 activity
  • TxB 2 thromboxane B 2
  • A23187 50 ⁇ M
  • PGE 2 production is measured after the addition of LPS (10 ⁇ g/mL) followed by overnight incubation. After incubation with A23187 or LPS the samples are centrifuged at 250 x g for 10 minutes at 4°C to collect serum. The amounts PGE 2 and TxB 2 present in the serum are measured using a chemiluminesence enzyme immunoassay from Assay Designs Inc. (Ann Arbor, Ml).
  • the levels of prostaglandin in each sample are normalized to the percent inhibition caused by each concentration of the test compound.
  • the percent inhibition data for each donor is pooled and fitted to a 4-parameter logistic function using a regression.
  • IC 50 values for compounds of formula (I) in the COX-2 inhibition assays are as low as about 0.010 ⁇ M.
  • Preferred are compounds for which the ratio of IC 50 values for COX-1 and COX-2 inhibition is above 50, advantageously in the range of about 100-1000 or higher.
  • LPS lipopolysaccharide
  • TXB 2 thromboxane B 2
  • Anti-inflammatory activity is determined using the carrageenan-induced rat paw edema assay following a modification of the procedure of Offerness et al., described in: Nonsteroidal Antiinflammatory Drugs, Lombardino, Ed., John Wiley & Sons, pp. 116-128 (1986).
  • Sprague Dawley rats (200-225 g) are fasted overnight, then orally dosed with the compound suspended in a fortified cornstarch solution. After one hour, a 0.1 mL volume of 1 % carrageenan in saline is injected into the sub-plantar region of the left hind paw which causes an inflammatory response. At three hours post-carrageenan, the rats are euthanized and both hind paws are cut off at the paw hair line and weighed on an electronic balance. The amount of edema in the inflamed paw is determined by subtracting the weight of the non-inflamed paw (right) from the weight of the inflamed paw (left). The percent inhibition by the compound is determined for each animal as the percent paw weight gained as compared to the control average.
  • the compounds of Examples 4(b) and 4(j) inhibit carrageenan-induced edema at 30 mg/kg p.o.
  • the gastric tolerability assay is used to assess gross ulceration in the rat, measured four hours after oral administration of the test compound.
  • the test is carried out as follows:
  • mice Male Sprague Dawley rats are fasted overnight, administered compound in fortified cornstarch vehicle by gavage and sacrificed by carbon dioxide inhalation four hours later. The stomachs are removed and gross gastric lesions counted and measured to give the total lesion length per rat. Each experiment contains the following groups (5-6 rats per group): vehicle control, test compounds and diclofenac as a reference compound.
  • Data are calculated as the mean number of ulcers in a group, the mean length of ulcers (mm) in the group and as the ulcer index (Ul).
  • Ul mean length of ulcers in a group x ulcer incidence where ulcer incidence is the fraction of animals in the group with lesions (100% incidence is 1).
  • the compounds of Examples 4(b) and 4(j) are essentially free of any gastric ulcerogenic effect at 30 mg/kg p.o.
  • Intestinal tolerability can be determined by measuring the effect on intestinal permeability. Lack of increase in permeability is indicative of intestinal tolerability.
  • the method used is a modification of a procedure by Davies et al., Pharm. Res., Vol. 11 , pp. 1652-1656 (1994) and is based on the fact that excretion of orally administered 51 Cr-EDTA, a marker of small intestinal permeability, is increased by NSAIDs.
  • Groups of male Sprague Dawley rats ( ⁇ 12 per group) are administered a single, oral dose of test compound or vehicle by gastric intubation.
  • each rat is administered 51 Cr-EDTA (5 ⁇ Ci per rat) by gastric intubation.
  • the rats are placed in individual metabolic cages and given food and water ad libitum. Urine is collected over a 24-hour period.
  • the rats are sacrificed.
  • the excreted 51 Cr-EDTA measured in the urine of compound-treated rats is compared to the excreted 51 Cr-EDTA measured in the urine of vehicle-treated rats.
  • Relative permeability is determined by calculating the activity present in each urine sample as a percent of the administered dose after correcting for background radiation.
  • the analgesic activity of the compounds of the invention is determined using the well-known Randall-Selitto assay.
  • the Randall-Selitto paw pressure assay measures anti-nociception (analgesic activity) in inflamed tissue by comparing the pressure threshold in the inflamed paw of the rat after oral administration of test drug with that in the inflamed paw of rats administered corn starch vehicle orally.
  • Hyperalgesia is induced by the injection of 0.1 mL of a 20% suspension of Brewer's yeast with a 26-gauge needle into the sub-plantar region of the right hind paw. The left paw is not injected and is used as the control paw for determination of hyperalgesia.
  • Vehicle fortified corn starch suspension 3%) at 10 mL/kg, reference compound (diclofenac is run in every experiment at the same dose as test compounds) and test compounds at different doses suspended in vehicle at 10 mUkg are administered orally two hours after the yeast injection.
  • the threshold for paw withdrawal is quantified with a Basile Analgesy-meter one hour after oral administration of test compounds.
  • the nociceptive threshold is defined as the force in grams at which the rat withdraws its foot or vocalizes. Either vocalization or foot withdrawal is recorded as a response.
  • the data are analyzed by comparing the mean pain threshold of the corn starch vehicle-treated group for the inflamed and non-inflamed paws to that of individual drug- treated rats. Individual rats in the drug-treated groups and positive control (diclofenac) group are called reactors if the individual pain threshold in each paw exceeds the control group mean threshold by two standard deviations of that mean.
  • the mean pain thresholds of the inflamed paw in the control group are compared to the individual pain thresholds of the inflamed paw in the test drug group.
  • the anti-arthritic effect of the compounds of the invention can be determined in the well-known chronic adjuvant arthritis test in the rat.
  • Ocular effects can be demonstrated in well-known ophthalmic assay methods.
  • anti-tumor activity can be demonstrated in well-known anti-tumor animal tests.
  • the compounds of formula (I) can be prepared, e.g., (a) by coupling a compound of formula (IV) or (IVa)
  • Z is iodo or bromo; R has meaning as defined above;
  • R a is hydrogen, an alkali metal cation or lower alkyl, preferably isopropyl; and R 13 and R 14 are lower alkyl; or R 13 and R 14 together with the nitrogen atom represent piperidino, pyrrolidino or morpholino;
  • A has meaning as defined herein which is in turn hydrogenolyzed and then hydrolyzed to obtain a compound of formula (I), wherein R represents, e.g., ethyl; or
  • R and A have meaning as defined herein, with a strong base; and in above processes, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired converting a free carboxylic acid of the invention into a pharmaceutically acceptable ester derivative thereof; and/or if desired, converting a resulting free acid into a salt or a resulting salt into the free acid or into another salt.
  • hydroxy protecting groups are those that can be converted under mild conditions into free amino, hydroxy and carboxyl groups without other undesirable side reactions taking place.
  • hydroxy protecting groups are preferably benzyl or substituted benzyl groups, or acyl groups, such as pivaloyl.
  • the preparation of compounds of formulae (VI) and (Via) according to process (a) is carried out under conditions of a modified Ullmann condensation for the preparation of diarylamines, e.g., in the presence of copper powder and copper (I) iodide and potassium carbonate, optionally in an inert high boiling solvent, such as nitrobenzene, toluene, xylene or ⁇ /-methylpyrrolidone, at elevated temperature, e.g., in the range of 100-200°C, preferably at reflux temperature, according to general methodology described by Nohara, Chem Abstr, Vol. 94, p. 15402x (1951); and Moser et al., J Med Chem, Vol. 33, p. 2358 (1990).
  • Z is bromo
  • the condensation is carried out in the presence of an iodide salt, e.g., potassium iodide.
  • Hydrolysis of the resulting ortho-anilinophenylacetamides of formula (VI) is carried out in aqueous alkali hydroxide, e.g., in 6N NaOH in the presence of an alcohol, e.g., ethanol, propanol and butanol, at elevated temperature, such as reflux temperature of the reaction mixture.
  • aqueous alkali hydroxide e.g., in 6N NaOH
  • an alcohol e.g., ethanol, propanol and butanol
  • esters of formula (Via) is carried out according to methods known in the art, e.g., under basic conditions as described above for the compounds of formula (VI) or alternatively under acidic conditions, e.g., using methanesulfonic acid.
  • the starting materials of formula (IV) or (IVa) are generally known or can be prepared using methodology known in the art, e.g. as described by Nohara in Japanese Patent Application No. 78/96,434 (1978); U.S. Patent No. 6,291,523 and as illustrated herein.
  • the corresponding anthranilic acid is converted to the ortho-diazonium derivative followed by treatment with an alkali metal iodide in acid, e.g., sulfuric acid, to obtain the 2-iodobenzoic acid or lower alkyl ester thereof.
  • acid e.g., sulfuric acid
  • Reduction to the corresponding benzyl alcohol e.g., with diborane or lithium aluminum hydride for the ester
  • conversion of the alcohol first to the bromide and then to the nitrile hydrolysis of the nitrile to the acetic acid and conversion to the /V, V-dialkylamide according to methodology known in the art yields a starting material of formula (IV).
  • the starting material of formula (IV), wherein Z is Br and R is cyclopropyl can be prepared by first condensing according to the method outlined in J. Am. Chem. Soa, Vol. 123, p. 4155 (2001), e.g., 2-bromo-5-iodobenzoic acid methyl ester with cyclopropyl bromide in the presence of indium trichloride to obtain 2-bromo-5- cyclopropylbenzoic acid methyl ester which is converted as described above to the corresponding 2-bromo-5-cyclopropylphenylacetamide of formula (IV).
  • the starting materials of formula (IV), wherein R is, e.g., ethyl can be prepared by Friedel-Crafts acetylation of oxindole with, e.g., acetyl chloride in the presence of aluminum chloride, reduction of the resulting ketone by, e.g., catalytic hydrogenolysis, followed by hydrolytic cleavage of the resulting 5-ethyloxindole to the ortho amino- phenylacetic acid. Diazotization in the presence of, e.g., potassium iodide yields the ortho iodo-phenylacetic acid which is converted to an amide of formula (IV).
  • Esters of formula (IVa) are prepared from the corresponding acids according to esterification methods known in the art.
  • amines of formula (V) are either known in the art or are prepared according to methods well-known in the art or as illustrated herein.
  • the biarylamines are prepared by condensation under conditions of a palladium catalyzed Suzuki coupling reaction of, e.g., an appropriately substituted 4-bromoaniline with an appropriately substituted phenylboronic acid.
  • cyclopropyl substituted anilines are prepared from the corresponding bromo substituted anilines (as the free amine or in protected form) by palladium catalyzed condensation with cyclopropyl boronic acid, according to methodology in Tetrahedron Letters, Vol. 43, p. 6987 (2002), and as illustrated in the examples.
  • 4-cycloalkyl substituted anilines are prepared by condensation of a 4-iodo or bromo substituted aniline protected, e.g., as a phthalimide derivative with, e.g., cyclopropyl bromide in the presence of indium trichloride followed by removal of the protecting group, similarly to general methodology in J Am Chem Soc, Vol. 123, p. 4155 (2001).
  • the preparation of, e.g., 5-ethyl or 5-/7-propyl substituted compounds according to process (b) is carried out under conditions of Friedel-Crafts acylation, e.g., in the presence of aluminum chloride in an inert solvent, such as 1,2-dichIoroethane, followed by hydrogenolysis, e.g., using palladium on charcoal catalyst, preferably in acetic acid as solvent, at room temperature and about 3 atmospheres pressure.
  • Friedel-Crafts acylation e.g., in the presence of aluminum chloride in an inert solvent, such as 1,2-dichIoroethane
  • hydrogenolysis e.g., using palladium on charcoal catalyst, preferably in acetic acid as solvent, at room temperature and about 3 atmospheres pressure.
  • the starting materials of formula (VII) are prepared generally as described under process (a) starting with an amide of formula (IV) in which R represents hydrogen, e.g., as described in Moser et al. (1990), supra.
  • the preparation of the compounds of the invention according to process (c) can be carried out under conditions known in the art for the hydrolytic cleavage of lactams, preferably with a strong aqueous base, such as aqueous sodium hydroxide, optionally in the presence of an organic water miscible solvent, such as methanol at elevated temperature in the range of about 50-100°C, as generally described in U.S. Patent No. 3,558,690.
  • a strong aqueous base such as aqueous sodium hydroxide
  • an organic water miscible solvent such as methanol
  • the oxindole starting materials are prepared by ⁇ /-acylation of a diarylamine of the formula (X)
  • R and A have meaning as defined above with a haloacetyl chloride, preferably chloroacetyl chloride, advantageously at elevated temperature, e.g., near 100°C, to obtain a compound of the formula (XI)
  • Cyclization of a compound of formula (XI) is carried out under conditions of Friedel-Crafts alkylation in an inert solvent, such as dichlorobenzene, in the presence of Friedel-Crafts catalysts, e.g., aluminum chloride and ethylaluminum dichloride, at elevated temperature, e.g., at 120-175°C.
  • Friedel-Crafts catalysts e.g., aluminum chloride and ethylaluminum dichloride
  • the stating amines of formula (X) can be prepared by an Ullmann condensation and other methods known in the art, e.g., a Buchwald coupling reaction.
  • Esters of the carboxylic acids of formula (I) are prepared by condensation of the carboxylic acid, in the form of a salt or in the presence of a base, with a halide (bromide or chloride) corresponding to the esterifying alcohol, such as benzyl chloroacetate, according to methodology well-known in the art, e.g., in a polar solvent, such as ⁇ /,/V-dimethylformamide, and if required further modifying the resulting product.
  • a polar solvent such as ⁇ /,/V-dimethylformamide
  • the esterification product is itself an ester, such can be converted to the carboxylic acid, e.g., by hydrogenolysis of a resulting benzyl ester.
  • the esterification product is itself a halide, such can for instance be converted to the nitrooxy derivative by reaction with, e.g., silver nitrate.
  • the compounds of formula (la) are preferably prepared by condensing a salt of a carboxylic acid of formula (I) above with a compound of formula
  • X is a leaving group
  • R b is a carboxy-protecting group to obtain a compound of formula (la) in carboxy- protected form, and subsequently removing the protecting group R b .
  • the esterification can be carried under esterification conditions known in the art, e.g., in a polar solvent, such as ⁇ /, ⁇ /-dimethylformamide, at a temperature range of room temperature to about 100°C, preferably at a range of 40-60°C.
  • a polar solvent such as ⁇ /, ⁇ /-dimethylformamide
  • the salt of the acid of formula (I) is preferably an alkali metal salt, e.g., the sodium salt which may be prepared in situ.
  • Leaving group X is preferably halo, e.g., chloro or bromo, or lower alkylsulfonyloxy, e.g., methanesulfonyloxy.
  • Carboxy-protecting group R b is preferably benzyl.
  • the resulting benzyl esters can be converted to the free acids of formula (la) preferably by hydrogenolysis with hydrogen in the presence of, e.g., Pd/C catalyst in acetic acid at atmospheric pressure or under Parr hydrogenation at a temperature ranging from room temperature to about 50°C.
  • the invention includes any novel starting materials and processes for their manufacture.
  • the acidic compounds of the invention may be converted into metal salts with pharmaceutically acceptable bases, e.g., an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained. Ammonium salts are obtained by reaction with the appropriate amine, e.g., diethylamine, and the like.
  • Compounds of the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, e.g., with inorganic acids, such as mineral acids, e.g., sulfuric acid, a phosphoric or hydrohalic acid; or with organic carboxylic acids, such as (CrC ⁇ alkanecarboxylic acids which, e.g., are unsubstituted or substituted by halogen, e.g., acetic acid, such as saturated or unsaturated dicarboxylic acids, e.g., oxalic, succinic, maleic orfumaric acid, such as hydroxycarboxylic acids, e.g., glycolic, lactic, malic, tartaric or citric acid, such as amino acids, e.g., aspartic or glutamic acid; or with organic sulfonic acids, such as (CrC ⁇ alkylsulfonic acids, e.g., methanesulf
  • a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
  • the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal, topical and parenteral administration to mammals, including man, to inhibit COX-2-activity, and for the treatment of COX-2 dependent disorders, and comprise an effective amount of a pharmacologically active compound of the invention, either alone or in combination with other therapeutic agents, and one or more pharmaceutically acceptable carriers.
  • compositions comprise an effective COX-2 inhibiting amount of a selective COX-2 inhibiting compound of the invention which is substantially free of COX-1 inhibiting activity and of side effects attributed thereto.
  • the pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application.
  • Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or e
  • compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, preferably about 1-50%, of the active ingredient.
  • Tablets may be either film coated or enteric coated according to methods known in the art.
  • Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier.
  • Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • Suitable formulations for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
  • Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like.
  • compounds of the present invention are capable of absorbing UV rays in the range of 290-320 nm while allowing passage of tanning rays at higher wavelengths. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Formulations suitable for topical application can be prepared, e.g., as described in U.S. Patent No. 4,784,808.
  • Formulations for ocular administration can be prepared, e.g., as described in U.S. Patent Nos. 4,829,088 and 4,960,799.
  • neoplasia malignant and benign
  • suitable additional active agents for use in relation to the treatment of neoplasia include, e.g., the anti-neoplastic agents or radioprotective agents recited in International Patent Application WO 98/16227 and the like.
  • Suitable additional therapeutic agents include analgesic agents, such as oxycodone, codeine, tramadol, levorphanol, propoxyphene, ketorolac, pentazocine, meperidine and the like; also anti-platelet agents, such as aspirin, clopidogrel, ticlopidine and the like; also bisphosphonates, such as zoledronate, pamidronate, risedronate, alendronate and the like; also statins, such as fluvastatin, atorvastatin, lovastatin, simvastatin, rosuvastatin, pitavastatin and the like.
  • analgesic agents such as oxycodone, codeine, tramadol, levorphanol, propoxyphene, ketorolac, pentazocine, meperidine and the like
  • anti-platelet agents such as aspirin, clopidogrel, ticlopidine and the like
  • bisphosphonates such as zoledronate,
  • a compound of the invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation.
  • the dosage of active compound administered is dependent on the species of warmblooded animal (mammal), the body weight, age and individual condition, and on the form of administration.
  • a unit dosage for oral administration to a mammal of about 50-70 kg may contain between about 5 mg and 500 mg, of the active ingredient.
  • the present invention also relates to methods of using the compounds of the invention and their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in mammals for inhibiting COX-2 and for the treatment of conditions as described herein, e.g., inflammation, pain, rheumatoid arthritis, osteoarthritis, dysmenorrheal, tumors and other COX-2-dependent disorders.
  • conditions as described herein e.g., inflammation, pain, rheumatoid arthritis, osteoarthritis, dysmenorrheal, tumors and other COX-2-dependent disorders.
  • the present invention relates to a method of selectively inhibiting COX-2 activity in a mammal without substantially inhibiting COX-1 activity, which comprises administering to a mammal in need thereof an effective COX-2 inhibiting amount of a compound of the invention.
  • the present invention also relates to a method of treating COX-2 dependent disorders in mammals, which comprises administering to a mammal in need thereof an effective COX-2 inhibiting amount of a compound of the invention.
  • the present invention relates to a method of treating COX-2 dependent disorders in mammals while substantially eliminating undesirable side effects associated with COX-1 inhibiting activity which comprises administering to a mammal in need thereof an effective COX-2 inhibiting amount of a selective COX-2 inhibiting compound of the invention which is substantially free of COX-1 inhibiting activity.
  • such relates to a method of, e.g., treating rheumatoid arthritis, osteoarthritis, pain, dysmenorrhea or inflammation in mammals without causing undesirable gastrointestinal ulceration, which method comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of the invention.
  • 2,3,5,6-Tetrafluoroaniline (25.0 g, 0.15 mol) is dissolved in methanol (100 mL) and treated with elemental bromine (28.4 g, 0.17 mol) by dropwise addition at room temperature. Solid sodium bicarbonate (15 g, 0.18 mol) is added portionwise and the resulting mixture stirred for an additional 2 hours. The reaction mixture is partitioned between Et 2 O (500 mL) and water (1000 mL). The organic layer is dried (MgSO 4 ) and evaporated by a rotary evaporator to give 2,3,5,6-tetrafluoro-4-bromoaniline (m.p. 59-60°C).
  • 2,3,5,6-Tetrafluoro-4-bromoaniline (13.8 g, 56.7 mmol) is dissolved in benzene (200 mL) and treated with 1.5 equivalents of phenylboronic acid (10.4 g, 85.1 mmol) and a catalytic amount of tetrakistriphenylphosphine palladium(O) (4.2 g, 3.6 mmol) as a solution in ethanol (30 mL). Sodium carbonate (60 mL of 2 M aqueous solution) is added and the reaction mixture stirred and heated to reflux temperature for 24 hours. After cooling to room temperature the mixture is partitioned between Et 2 O (500 mL) and water (250 mL).
  • 2,6-Dichloroaniline (16.2 g, 0.1 mol) is suspended in a solution of sodium bicarbonate (8.6 g, 0.1 mol in 100 mL of water) and warmed to 60°C. Elemental iodine (25.4 g, 0.1 mol) is added portionwise and the resulting mixture stirred at 60°C for 3 days. After cooling to room temperature, the reaction mixture is partitioned between CH 2 CI 2 (250 mL) and saturated sodium bisulfite solution (500 mL). The aqueous layer is re-extracted with additional CH 2 CI 2 (250 mL) and the combined organic layers dried (MgSO 4 ) and concentrated by rotary evaporator.
  • sodium bicarbonate 8.6 g, 0.1 mol in 100 mL of water
  • Elemental iodine (25.4 g, 0.1 mol) is added portionwise and the resulting mixture stirred at 60°C for 3 days. After cooling to room temperature, the reaction mixture is partitioned between
  • 2-Fluoro-6-chloroaniline (28.8 g, 0.2 mol) is suspended in a solution of sodium bicarbonate (17.2 g, 0.2 mol in 150 mL water) and warmed to 60°C. Elemental iodine (50.8 g, 0.2 mol) is added portionwise and the resulting mixture stirred at 60°C for 3 days. After cooling to room temperature, the reaction mixture is partitioned between CH 2 CI 2 (350 mL) and saturated sodium bisulfite solution (500 mL). The aqueous layer is re- extracted with additional CH 2 CI 2 (250 mL) and the combined organic layers dried (MgSO 4 ) and concentrated by rotary evaporator. The residual oil is purified by flash chromatography (9:1 hexanes/EtOAc) to give 2-fluoro-4-iodo-6-chloroaniline (m.p. 85-87°C).
  • 2-Fluoro-4-iodo-6-chloroaniline (8.0 g, 36.0 mmol) is dissolved in DMF (110 mL) and treated with 2.8 equivalents of phenylboronic acid (10.0 g, 82 mmol), and a catalytic amount of tetrakistriphenylphosphine palladium(O) (3.0 g, 2.6 mmol) as a solution in DMF (20 mL).
  • Sodium carbonate (30 mL of 2 M aqueous solution) is added and the reaction mixture stirred and heated to 100°C for 24 hours. After cooling to room temperature most of the DMF is removed by rotary evaporator under high vacuum.
  • 2-Fluoro-4-bromoaniline (10.7 g), 4-fluorophenylboronic acid (11.9 g), 60 mL of 2 N NaOH and 200 mL of benzene are combined and degassed with N 2 .
  • Palladium tetrakistriphenylphosphine (4.2 g) is_added and the mixture stirred at reflux temperature overnight. After cooling, the reaction is filtered through Celite and concentrated. The oily residue is purified by flash chromatography (5-10% EtOAc/hexane) to afford 2-fluoro-4-(4'- fluorophenyl)aniline as a solid.
  • 4-Cyclohexylaniline (20 g, 114 mmol) is dissolved in acetic acid (50 mL) and stirred with acetic anhydride (12 g, 114 mol). The reaction is exothermic and the mixture is allowed to cool to room temperature, then stirred for 2 additional hours. The volatiles are removed by rotary evaporator and the residual solid triturated with hexane and filtered to give 4-cyclohexylacetanilide (m.p. 126-128°C). 4-Cyclohexylacetanilide (24 g, 110 mmol) is dissolved in a mixture of concentrated HCI (25 mL) and acetic acid (75 mL).
  • the mixture is allowed to warm to room temperature and stirred overnight under an atmosphere of nitrogen.
  • the mixture is poured over 20 g of ice and is extracted three times with 20 mL of CH 2 CI 2 .
  • the combined organic layers are washed with 20 mL each of water, saturated aqueous sodium bicarbonate and saturated brine, and dried over magnesium sulfate.
  • the mixture is filtered and the solvents are removed in vacuo to give an oil which is purified by flash chromatography on silica gel (CH 2 CI 2 ) to give 1 -chloro 2-acetylaminonaphthalene as a solid.
  • 5-Acetylaminoindane (8.8 g) is dissolved in a solution of 26 mL of HOAc and 126 mL of acetic anhydride, and cooled to 0°C.
  • Nitric acid (8.3 mL) is added carefully dropwise to the solution so as to control the temperature of the exothermic reaction. The mixture is stirred for an additional 30 minutes and is poured onto ice and filtered. The solid is washed with water and dried in a vacuum oven overnight to give 5-acetylamino-6-nitroindane that is used without further purification.
  • a mixture of this solid in 230 mL of 6 N HCI is heated to reflux for 4 hours. The mixture is neutralized with Na 2 CO 3 (152 g) in 1000 mL of H 2 O. The solids are filtered and dried overnight in a vacuum oven to give 5-amino-6-nitroindane.
  • 5-Amino-6-nitroindane (4 g) is dissolved in 10 mL of MeOH, 30 mL of H 2 O and 20 mL of H 2 SO 4 , and cooled to 0°C.
  • a solution of 1.72 g of NaNO 2 (24.9 mmol) in 5 mL of H 2 O is added dropwise, keeping the temperature of the reaction below 8°C.
  • the mixture is allowed to stir for 30 minutes.
  • This mixture is then added dropwise to a mixture of CuBr (1.8 g, 12.5 mmol) and 6 mL of 48% HBr in 30 mL of H 2 O that is heated to 60°C.
  • the reaction is cooled and added to H 2 O and EtOAc.
  • 4-Bromo-2-fluoro-3-trifluoromethylaniline is prepared from 2-fluoro-3- trifluoromethylaniline by treatment with NBS in DMF according to the procedure described in International Application WO 94/18179.
  • 4-Cyclopropyl-2-fluoro-3-trifluoromethylaniline is prepared from 4-bromo-2-fluoro-3- trifluoromethylaniline by palladium-catalyzed coupling to cyclopropylboronic acid, similarly to the method outlined in Tetrahedron Letters, Vol. 43, p. 6987 (2002).
  • 3,5-Difluoroaniline (10.0 g, 77.5 mmol) is dissolved in DMF (100 mL).
  • NBS (13.9 g, 78.0 mmol) is added portionwise at room temperature. After stirring overnight at room temperature, the reaction mixture is diluted with Et 2 O and washed with brine. The separated organic phase is dried (Na 2 SO 4 ) and concentrated to give an oil which is purified by column chromatography (methylene chloride/hexanes) to give 4-bromo-3,5-difluoroaniline.
  • 4-Bromo-3,5-difluoroaniline (10.5 g, 50.5 mmol) is dissolved in DMF (100 mL).
  • NCS (28.6 g, 50.5 mmol) is added portionwise at room temperature. After 48 hours, the reaction is diluted with Et 2 O and washed with brine. The separated organic phase is dried (Na 2 SO 4 ) and concentrated to give an oil. The residue is purified by column chromatography (EtOAc/hexanes) to give 4-bromo-2-chloro-3,5-difluoroaniline.
  • 2-Chloro-5-methyl-6-fluorobenzoic acid (43 g, 0.25 mol) is suspended in CH 2 CI (500 mL) and treated with thionyl chloride (36 mL, 0.49 mol) by dropwise addition, immediately followed by the addition of several drops (0.1 mL) of DMF.
  • the mixture is heated to reflux temperature and stirred for 12 hours during which time the solid completely dissolves and a clear solution is obtained.
  • most of the solvent is removed by rotary evaporator and toluene (500 mL) is added.
  • the solution is again concentrated by rotary evaporator to remove residual thionyl chloride.
  • the light yellow oil that results is filtered through a plug of cotton and dissolved in CH CI (1000 mL).
  • the organic layer is washed with brine (500 mL), dried (MgSO 4 ) and concentrated by rotary evaporator.
  • the white solid, which results, is triturated with hexanes/Et 2 O (4:1, 500 mL) and collected to provide 2-chloro-5-methyl-6-fluorobenzamide as a white solid (m.p. 151-153°C).
  • a solution of sodium methoxide is generated by treating metallic sodium (29 g, 1.26 mol) with 1000 mL of anhydrous methanol by dropwise addition under an inert atmosphere. After the metal is completely consumed, the solution is heated at reflux temperature for 30 minutes and then cooled to room temperature. 2-Chloro-5-methyl-6- fluorobenzamide (42 g, 0.22 mol) is added and stirring continued for an additional 30 minutes at room temperature. ⁇ /-Bromosuccinimide (78 g, 0.44 mol) is then slowly added via a powder additional funnel. The reaction mixture is warmed to 60°C for 3 hours during which time foaming is observed. The reaction mixture is cooled to room temperature and most of the solvent is removed by rotary evaporator.
  • ⁇ -(2-chloro-5-methyl-6-fluorophenyl)-carbamic acid methyl ester 39 g, 0.18 mmol is dissolved in MeOH (150 mL), water (150 mL) and 30% NaOH solution (150 mL). The reaction mixture is heated to reflux temperature for 3 days and then cooled to room temperature. The reaction is concentrated by rotary evaporator to remove most of the methanol and then partitioned between Et 2 O (500 mL) and water (500 mL). The aqueous phase is extracted again with Et 2 O (250 mL) and the combined organic layers washed with brine (500 mL), dried and concentrated by rotary evaporator.
  • the crude product is purified by bulb-to-bulb distillation to give 2-chloro-5-methyl-6-fluoroaniline as a colorless oil (b.p. 120-131 °C at ⁇ 20 mm of Hg), which forms a white crystalline solid upon storage at 4°C.
  • the crude material is purified using flash chromatography (20% CH 2 CI 2 /hexanes ) and then further purified by bulb-to-bulb distillation (b.p. 155-165°C at ⁇ 20 mm of Hg) to give 2-chloro-4-bromo-5-methyl-6-fluoroaniline as a peach-colored solid which is re-crystallized from ice-cold hexanes (m.p. 67-71 °C).
  • a solution of lithium diiosopropyl amide is generated by adding n-BuLi (360 mL of 2 M solution in THF) to diisopropylamine (73 g, 0.722 mol) in 500 mL of anhydrous THF while a reaction temperature of -60°C is maintained by cooling in dry-ice acetone bath. After stirring for 30 minutes, 1-bromo-4-chloro-2-fluorobenzene (75 g, 0.36 mol) is added and stirring maintained at -70 C C for 2 hours. The cold solution is then transferred, via a cannula, under an inert atmosphere to a suspension of solid CO 2 (100 g, excess) in anhydrous Et 2 O.
  • the mixture is allowed to warm to room temperature with stirring and then the solvent removed by rotary evaporator.
  • the white solid that is obtained is suspended in 1000 mL of 2 N HCI solution and stirred for an additional 1 hour.
  • the suspension is filtered to collect a white solid which is air dried, suspended in 100 mL of hexanes and collected to give 2-chloro-5-bromo-6-fluorobenzoic acid.
  • 2-Chloro-5-bromo-6-fluorobenzoic acid (91 g, 0.36 mol) is suspended in CH 2 CI 2 (200 mL) and treated with oxalyl chloride (51 g, 0.40 mol) by dropwise addition, immediately followed by the addition of several drops (0.1 mL) of DMF. The mixture is stirred at room temperature for 3 hours during which time the solid completely dissolves and a clear solution is obtained. The solvent is removed by rotary evaporator and the residue is added to 1000 mL of ammonium hydroxide while stirring at 0°C. The product is collected by filtration and washed with water to give 2-chloro-5-bromo-6-fluorobenzamide as a white solid.
  • a solution of sodium methoxide is generated by treating metallic sodium (18 g, 0.78 mol) with 1000 mL of anhydrous methanol by dropwise addition under an inert atmosphere.
  • the mixture is heated to 95°C for 4 days and then cooled to room temperature.
  • the reaction mixture is partitioned between EtOAc (500 mL) and water (500 mL).
  • the organic phase is washed with water (2 x 250 mL), brine (500 mL) and then dried (MgSO 4 ) and concentrated by rotary evaporator.
  • the crude product is purified using flash chromatography (7-14% EtOAc/hexanes). After evaporation of the appropriate fractions the product is further purified by treating a solution in Et 2 O (100 mL) with charcoal, followed by filtration through Celite and evaporation. ⁇ /-(2-chloro-5- cyclopropyl-6-fluorophenyI)-carbamic acid methyl ester is obtained as a white crystalline solid (m.p. 100-102°C).
  • 6-Bromo-4-chloro-2-fluoroaniline (2.0 g, 8.91 mmol), cyclopropylboronic acid (1.53 g, 17.8 mmol), K 3 PO (6.61 g, 31.2 mmol) and tricyclohexyl phosphine (0.249 g, 0.89 mmol) are dissolved in toluene (31 mL) and water (10 mL). The solution is degassed with N 2 , heated to 90°C, and Pd(OAc) 2 (0.25 g, 1.16 mmol) is added.
  • reaction mixture is heated at 100°C for 18 hours, cooled over 48 hours and loaded directly on a column of silica gel for purification by column chromatography (EtOAc/hexanes) to give 2-fluoro-4-chloro-6- cyclopropylaniline.
  • 1,4-Dibromo-2,5-difluorobenzene (100 g, 0.37 mol) is dissolved in concentrated sulfuric acid (200 g) and treated with fuming nitric acid (56 g, 0.44 mol, HNO 3 content >90%) by drop-wise addition at an internal temperature that is maintained between 50-60°C. After the addition is complete, the mixture is cooled to room temperature and stirred for 12 hours, then poured into ice-water (1000 mL). The suspension is extracted with EtOAc (3 x 500 mL). The combined organic extracts are dried (MgSO 4 ) and concentrated by rotary evaporator to give 2,5-dibromo-3,6-difluoronitrobenzene as an oily yellow solid.
  • 2,5-Dibromo-3,6-difluoronitrobenzene 120 g, 0.37 mol is dissolved in a mixture of ethanol (300 mL) and concentrated HCI (500 mL). The mixture is heated to 80°C and treated with iron powder (100 g, 1.78 mol) by portion-wise addition over 2 hours. After stirring for an additional hour, the mixture is cooled to room temperature and EtOAc (800 mL) is added. The solids are removed by filtration and then the solution concentrated by rotary evaporator to remove most of the solvent. The residue is partitioned between EtOAc (1000 mL) and water (500 mL).
  • 2,5-Dibromo-3,6-difluoroaniline (50g, 0.17 mol) is dissolved in glacial acetic acid (100 mL), stirred at room temperature, and treated with acetic anhydride (50g, 0.49 mol). The reaction mixture becomes warm and is then allowed to cool to room temperature over the next 3 hours. The mixture is poured into EtOAc (500 mL) and extracted with water (2 x 300 mL), saturated sodium bicarbonate solution (2 x 300 mL) and then brine (2 x 300 mL).
  • 6-fluoro-2-naphthoic acid ethyl ester 600 mg, 2.75 mmol
  • ethanol 10 mL
  • 1 N NaOH 2.75 mL, 2.75 mmol
  • water 10 mL
  • Acidification (2 N HCI) and filtration gives 6-fluoro-2-naphthoic acid as a white solid.
  • 4-Amino-2,7-tj/s(trifluoromethyl)quinoline is similarly prepared from 4-chloro-2,7- bis(trifluoromethyl)quinoIine using ammonia in methanol and is purified by flash chromatography on silica gel (10% EtOAc in hexanes).
  • 4-Amino-7-fluoroquinoline is similarly prepared from 4-chloro-7-fluoroquinoline.
  • a mixture of 4-chloro-6-fluoro-2-(trifluoromethyl)quinoline (1 g, 4.01 mmol) and NH 3 (3 mL) in ethylene glycol (20 mL) is prepared at -78°C in a sealed tube. After warming up to room temperature, the sealed tube is gradually heated to 100°C overnight. After cooling to -78°C, the sealed tube is opened and the contents are concentrated by rotary evaporator. The residue is purified by flash chromatography on silica gel (1:3 EtOAc/hexanes) to give 4-amino-6-fIuoro-2-(trifluoromethyl)quinoline as a light yellow solid.
  • 5-Methoxy-2-bromophenylacetonitrile (52.8 g, 0.23 mol) is dissolved in ethanol (250 mL) and stirred at room temperature.
  • Sodium hydroxide (9.3 g, 0.47 mol) is dissolved in water (150 mL) and added to the solution of the nitrile.
  • the mixture is heated to reflux temperature for 12 hours and then cooled to room temperature.
  • Most of the ethanol is removed using a rotary evaporator and the residual aqueous solution adjusted to pH 4 with 3 N HCI.
  • the solid which forms is isolated by filtration and washed with water. Air drying gives 5-methoxy-2-bromophenylacetic acid.
  • 5-Methoxy-2-bromophenylacetyl chloride 60 g, 0.23 mol is dissolved in anhydrous Et 2 O (400 mL), stirred and cooled in an ice bath. A 2 M solution of dimethylamine (228 mL, 0.46 mol) is added dropwise and the mixture allowed to warm to room temperature and stirred for 2 hours. Additional Et 2 O (500 mL) is added. The organic solution is washed with 1 N HCI (2 x 500 mL), saturated NaHCO 3 (500 mL) and brine (500 mL). The organic layer is dried (Na 2 SO 4 ) and concentrated by rotary evaporator.
  • the 5-trifluoromethoxy-2-iodobenzoic acid is converted to ⁇ /, ⁇ /-dimethyl-2-iodo-5- trifluoromethoxyphenylacetamide similarly to previously described procedures.
  • a mixture of 4-aminobenzotrifluoride (100 g, 0.62 mol) and di-terf-butyl carbonate (150 g, 0.69 mol) in anhydrous THF (400 mL) is heated at reflux temperature for 6 hours and then cooled to room temperature. Most of the solvent is removed using a rotary evaporator and the non-volatile material that remains is triturated with water (1000 mL) to form a solid. The solid is isolated by filtration and washed with additional water (500 mL), then washed with hexanes (500 mL) to give 4-(BOC-amino)benzotrifluoride (m.p. 123-124°C).
  • reaction is quenched by addition of saturated aqueous ammonium chloride (500 mL).
  • the mixture is partitioned between 1 N HCI (500 mL) and EtOAc (500 mL).
  • the organic layer is washed with brine (400 mL), dried (MgSO ) and concentrated by rotary evaporator to give crude product which is purified by flash chromatography (10:1 hexanes/methanol) to give 4-(BOC-amino)-5- trifluoromethylbenzoic acid (m.p. 197-198°C).
  • 5-Trifluoromethylanthranilic acid 43 g, 0.21 mol is suspended in a mixture of concentrated HCI (40 mL) and water (240 mL), cooled to 0°C and stirred.
  • Sodium nitrite (18 g, 0.26 mol) is dissolved in water (50 mL) and slowly added taking care to maintain the temperature of the reaction mixture below 5°C. Stirring is continued at 0°C for 30 minutes.
  • Potassium iodide (65 g, 0.39 mol) is dissolved in a mixture of concentrated H 2 SO 4 (15 mL) and water (100 mL) and the solution is added dropwise to the reaction mixture while keeping the temperature below 10°C.
  • 5-Trifluoromethyl-2-iodobenzyl alcohol (45 g, 0.15 mol) is dissolved in anhydrous Et 2 O (400 mL) and treated with phosphorous tribromide (41 mL, 0.15 mol) by dropwise addition.
  • the reaction mixture is stirred at room temperature overnight and quenched by slow addition of water (150 mL).
  • the organic layer is separated, washed with saturated aqueous NaHCO 3 (250 mL), brine (250 mL), dried (MgSO 4 ) and concentrated by rotary evaporator to give 5-trifluoromethyl-2-iodobenzyl bromide as an oil.
  • a solution of 5-trifluoromethyl-2-iodophenylacetonitrile (30 g, 96 mmol) in ethanol (100 mL) is stirred at room temperature.
  • Sodium hydroxide (7.7 g, 192 mmol) dissolved in water (60 mL) is added.
  • the mixture is heated to reflux temperature for 12 hours and then cooled to room temperature.
  • Most of the ethanol is removed using a rotary evaporator and the residual aqueous solution adjusted to pH 4 with 3 N HCI.
  • the solid which forms is isolated by filtration and washed with water (250 mL) and then hexanes (500 mL). Air drying gives 5-trifluoromethyl-2-iodophenylacetic acid.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle R représente hydrogène, alkyle inférieur, cycloalkyle (C3-C6), hydroxy, halo, alkoxy inférieur, trifluorométhoxy, trifluorométyhle ou cyano et A représente diaryle, β-naphtyle éventuellement substitué, aryle hétérocyclique bicyclique, aryle carbocyclique monocyclique de cycloalkyle (C3-C6) ou aryle carbocyclique monocyclique fondu de cycloalcane (C5 ou C6), des sels de ceux-ci, acceptables d'un point de vue pharmaceutique, ainsi que des esters de ceux-ci, acceptables d'un point de vue pharmaceutique, utilisés dans le traitement de troubles dépendant de COX-2.
PCT/EP2003/013246 2002-11-26 2003-11-25 Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2) WO2004048314A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03767652A EP1567477B1 (fr) 2002-11-26 2003-11-25 Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2)
JP2004554464A JP4580240B2 (ja) 2002-11-26 2003-11-25 置換アミノフェニル酢酸、その誘導体、その製造およびシクロオキシゲナーゼ２（ｃｏｘ−２）阻害剤としてのその使用
AU2003292112A AU2003292112A1 (en) 2002-11-26 2003-11-25 Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
AT03767652T ATE442348T1 (de) 2002-11-26 2003-11-25 Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
BR0316615-5A BR0316615A (pt) 2002-11-26 2003-11-25 ácidos amino fenilacéticos substiuìdos, seus derivados, sua preparação e seu uso como inibidores da ciclooxigenase 2 (cox-2)
CA002507458A CA2507458A1 (fr) 2002-11-26 2003-11-25 Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2)
DE60329219T DE60329219D1 (de) 2002-11-26 2003-11-25 Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42922202P 2002-11-26 2002-11-26
US60/429,222 2002-11-26

Publications (1)

Publication Number Publication Date
WO2004048314A1 true WO2004048314A1 (fr) 2004-06-10

Family

ID=32393527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013246 WO2004048314A1 (fr) 2002-11-26 2003-11-25 Acides amino phenylacetiques substitues, derives de ceux-ci, procede pour les preparer et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2)

Country Status (15)

Country Link
US (1) US7202364B2 (fr)
EP (2) EP2090566A3 (fr)
JP (2) JP4580240B2 (fr)
CN (1) CN1729157A (fr)
AR (1) AR042206A1 (fr)
AT (1) ATE442348T1 (fr)
AU (1) AU2003292112A1 (fr)
BR (1) BR0316615A (fr)
CA (1) CA2507458A1 (fr)
DE (1) DE60329219D1 (fr)
ES (1) ES2333316T3 (fr)
PE (1) PE20040844A1 (fr)
PT (1) PT1567477E (fr)
TW (1) TW200424152A (fr)
WO (1) WO2004048314A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005909A1 (fr) * 2004-07-08 2006-01-19 Astrazeneca Ab Acides substitues pour le traitement de maladies respiratoires
WO2007096058A1 (fr) * 2006-02-21 2007-08-30 Bayer Cropscience Ag Cétoénols cycliques à substitution cycloalkyl-phényle
WO2008002853A3 (fr) * 2006-06-26 2008-02-07 Novartis Ag Dérivés d'acide phénylacétique
JP2008513391A (ja) * 2004-09-16 2008-05-01 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト ヨード−フェニル置換された環状ケトエノール
JP2009519308A (ja) * 2005-12-15 2009-05-14 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
US7737135B2 (en) 2004-08-24 2010-06-15 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
WO2011045059A1 (fr) * 2009-10-16 2011-04-21 Almirall, S.A. Procédé de fabrication d'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
US8003703B2 (en) 2003-08-21 2011-08-23 Astrazeneca Ab Phenoxiacetic acid derivatives
US8008350B2 (en) 2005-10-06 2011-08-30 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
JP2012056962A (ja) * 2004-06-24 2012-03-22 Vertex Pharmaceuticals Inc Ａｔｐ結合カセットトランスポーターのモジュレーター
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
US8158820B2 (en) 2003-04-07 2012-04-17 Astrazeneca Ab Compounds
US8258308B2 (en) 2006-12-22 2012-09-04 Laboratorios Almirall, S.A. Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
US8501943B2 (en) 2009-03-13 2013-08-06 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
US8507544B2 (en) 2007-07-05 2013-08-13 Astrazeneca Ab Bi-aryl amide compounds as CRTh2 receptor modulators
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
US8536165B2 (en) 2007-08-10 2013-09-17 Almirall, S.A. Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US8835639B2 (en) 2009-03-20 2014-09-16 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8865728B2 (en) 2008-06-20 2014-10-21 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
EP2060566B1 (fr) * 2006-01-13 2016-06-08 Dow AgroSciences LLC Aryles poly-substitués
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CN113620874A (zh) * 2021-08-10 2021-11-09 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
US11970469B2 (en) 2018-06-04 2024-04-30 The Institute Of Cancer Research: Royal Cancer Hospital Compounds useful in the treatment of disorders associated with mutant RAS

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
CA2622545A1 (fr) * 2005-10-18 2007-04-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Derives de naphtyle inhibiteurs de l'agregation de beta-amyloide
WO2008048577A1 (fr) * 2006-10-17 2008-04-24 Milestone Pharmaceuticals Inc. Procédés d'utilisation de 4-phénylaminoquinolines en tant que composés topiques anti-inflammatoires non stéroïdes
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
US9125901B2 (en) 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
CA2848577C (fr) * 2010-01-04 2016-02-16 Nippon Soda Co., Ltd. Compose heterocyclique contenant de l'azote et germicide agricole/horticole
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
CN108530310A (zh) * 2017-03-02 2018-09-14 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
CN109721565B (zh) * 2017-10-27 2020-09-15 都创(上海)医药科技有限公司 一种重要的氟中间体合成工艺

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51149252A (en) * 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
JPS5268159A (en) * 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) * 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
WO1998016227A1 (fr) 1996-10-15 1998-04-23 G.D. Searle & Co. Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
WO1999011605A1 (fr) 1997-08-28 1999-03-11 Novartis Ag Certains acides 5-alkyl-2-arylaminophenylacetiques et leurs derives
WO2000076969A1 (fr) * 1999-06-10 2000-12-21 Warner-Lambert Company Procede d'inhibition d'agregation de proteines amyloides et d'imagerie de depots amyloides au moyen de derives d'isoindoline

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3637710A (en) * 1969-05-26 1972-01-25 Geigy Chem Corp 4-(phenylimino)-1 4-dihydroquinoline derivatives
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
JPS5396434A (en) 1977-02-03 1978-08-23 Yokogawa Hokushin Electric Corp Synchronizing rectifier circuit
AT370721B (de) 1981-02-24 1983-04-25 Ciba Geigy Ag Verfahren zur herstellung von neuen salzen der 2- (2,6-dichloranilino)-phenylessigsaeure, der
ES8404783A1 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
DE3612537C1 (de) 1986-04-14 1987-07-16 Dispersa Ag Arzneimittel zur Behandlung von Entzuendungen im Auge
US4960799A (en) 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5068250A (en) 1988-09-29 1991-11-26 Trustees Of University Of Pennsylvania Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites
EP0510756B1 (fr) 1991-04-24 1997-12-10 Koninklijke Philips Electronics N.V. Récupérateur de rythme pour récepteurs à processeur de Viterbi
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
GB9302071D0 (en) 1993-02-03 1993-03-24 Rhone Poulenc Agriculture Compositions of matter
ES2132672T3 (es) 1994-06-29 1999-08-16 Novartis Ag Nuevas sales de acido 2-((2,6-diclorofenil)amino)fenil-acetoxiacetico con cationes basicos organicos.
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US6355680B1 (en) 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
GB9922830D0 (en) 1999-09-27 1999-11-24 Novartis Ag Processes
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
AR030630A1 (es) 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51149252A (en) * 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
JPS5268159A (en) * 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) * 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
WO1998016227A1 (fr) 1996-10-15 1998-04-23 G.D. Searle & Co. Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
WO1999011605A1 (fr) 1997-08-28 1999-03-11 Novartis Ag Certains acides 5-alkyl-2-arylaminophenylacetiques et leurs derives
US6291523B1 (en) 1997-08-28 2001-09-18 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
WO2000076969A1 (fr) * 1999-06-10 2000-12-21 Warner-Lambert Company Procede d'inhibition d'agregation de proteines amyloides et d'imagerie de depots amyloides au moyen de derives d'isoindoline

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BREWSTER, ORG. SYNTH. II, 1943, pages 347
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 117725C
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 22459A
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 5725 W
CHEMICAL ABSTRACTS, vol. 87, no. 1, 4 July 1977, Columbus, Ohio, US; abstract no. 5725w, page 461; column 1; XP002273660 *
CHEMICAL ABSTRACTS, vol. 87, no. 15, 10 October 1977, Columbus, Ohio, US; abstract no. 117725c, page 585; column 2; XP002273659 *
CHEMICAL ABSTRACTS, vol. 88, no. 3, 16 January 1978, Columbus, Ohio, US; abstract no. 22459a, page 596; column 1; XP002273661 *
DENNY W A ET AL: "Potential antitumor gents. 26. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 25, no. 3, 1 March 1982 (1982-03-01), pages 276 - 315, XP002081503, ISSN: 0022-2623 *
J MED CHEM, vol. 33, 1990, pages 2358 - 2368
OFFERNESS ET AL.: "Nonsteroidal Antiinflammatory Drugs", 1986, JOHN WILEY & SONS, pages: 116 - 128

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158820B2 (en) 2003-04-07 2012-04-17 Astrazeneca Ab Compounds
US8003703B2 (en) 2003-08-21 2011-08-23 Astrazeneca Ab Phenoxiacetic acid derivatives
US8394986B2 (en) 2003-08-21 2013-03-12 Astrazeneca Ab Phenoxiacetic acid derivatives
US9090619B2 (en) 2004-06-24 2015-07-28 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2012056962A (ja) * 2004-06-24 2012-03-22 Vertex Pharmaceuticals Inc Ａｔｐ結合カセットトランスポーターのモジュレーター
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2006005909A1 (fr) * 2004-07-08 2006-01-19 Astrazeneca Ab Acides substitues pour le traitement de maladies respiratoires
US8022248B2 (en) 2004-07-08 2011-09-20 Astrazeneca Ab Substituted acids for the treatment of respiratory diseases
JP4869225B2 (ja) * 2004-07-08 2012-02-08 アストラゼネカ・アクチエボラーグ 呼吸器疾患処置用の置換酸
CN101014564B (zh) * 2004-07-08 2012-05-09 阿斯利康(瑞典)有限公司 用于治疗呼吸***疾病的取代酸
CN102557971A (zh) * 2004-07-08 2012-07-11 阿斯利康(瑞典)有限公司 用于治疗呼吸***疾病的取代酸
CN102557971B (zh) * 2004-07-08 2015-06-17 阿斯利康(瑞典)有限公司 用于治疗呼吸***疾病的取代酸
JP2008505874A (ja) * 2004-07-08 2008-02-28 アストラゼネカ・アクチエボラーグ 呼吸器疾患処置用の置換酸
US7737135B2 (en) 2004-08-24 2010-06-15 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8722741B2 (en) 2004-08-24 2014-05-13 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8163727B2 (en) 2004-08-24 2012-04-24 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
JP2008513391A (ja) * 2004-09-16 2008-05-01 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト ヨード−フェニル置換された環状ケトエノール
US8629084B2 (en) 2004-09-16 2014-01-14 Bayer Cropscience Ag Iodine-phenyl-substituted cyclic cetoenols
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8349897B2 (en) 2005-10-06 2013-01-08 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8008350B2 (en) 2005-10-06 2011-08-30 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8415394B2 (en) 2005-10-06 2013-04-09 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
JP2009519308A (ja) * 2005-12-15 2009-05-14 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2060566B1 (fr) * 2006-01-13 2016-06-08 Dow AgroSciences LLC Aryles poly-substitués
WO2007096058A1 (fr) * 2006-02-21 2007-08-30 Bayer Cropscience Ag Cétoénols cycliques à substitution cycloalkyl-phényle
US8013172B2 (en) 2006-02-21 2011-09-06 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
JP2013100310A (ja) * 2006-02-21 2013-05-23 Bayer Cropscience Ag シクロアルキルフェニル置換環状ケトエノール
US8541617B2 (en) 2006-02-21 2013-09-24 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
JP2009527513A (ja) * 2006-02-21 2009-07-30 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト シクロアルキルフェニル置換環状ケトエノール
US8362294B2 (en) 2006-06-26 2013-01-29 Novartis Ag Phenylacetic acid derivatives
AU2007265181B2 (en) * 2006-06-26 2010-11-25 Novartis Ag Phenylacetic acid derivatives as COX-2 inhibitors
US8586782B2 (en) 2006-06-26 2013-11-19 Novartis Ag Phenylacetic acid derivatives
WO2008002853A3 (fr) * 2006-06-26 2008-02-07 Novartis Ag Dérivés d'acide phénylacétique
US8691852B2 (en) 2006-12-22 2014-04-08 Amirall, S.A. Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
US8258308B2 (en) 2006-12-22 2012-09-04 Laboratorios Almirall, S.A. Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
US8507544B2 (en) 2007-07-05 2013-08-13 Astrazeneca Ab Bi-aryl amide compounds as CRTh2 receptor modulators
US8536165B2 (en) 2007-08-10 2013-09-17 Almirall, S.A. Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8865728B2 (en) 2008-06-20 2014-10-21 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
US8501943B2 (en) 2009-03-13 2013-08-06 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
US9371287B2 (en) 2009-03-20 2016-06-21 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8835639B2 (en) 2009-03-20 2014-09-16 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8598363B2 (en) 2009-10-16 2013-12-03 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′biphenyl-4-yl)amino]nicotinic acid
WO2011045059A1 (fr) * 2009-10-16 2011-04-21 Almirall, S.A. Procédé de fabrication d'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
EP2314577A1 (fr) * 2009-10-16 2011-04-27 Almirall, S.A. Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US11970469B2 (en) 2018-06-04 2024-04-30 The Institute Of Cancer Research: Royal Cancer Hospital Compounds useful in the treatment of disorders associated with mutant RAS
CN113620874A (zh) * 2021-08-10 2021-11-09 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
CN113620874B (zh) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途

Also Published As

Publication number Publication date
AR042206A1 (es) 2005-06-15
US7202364B2 (en) 2007-04-10
ATE442348T1 (de) 2009-09-15
PT1567477E (pt) 2009-12-14
ES2333316T3 (es) 2010-02-19
PE20040844A1 (es) 2004-12-30
EP2090566A3 (fr) 2009-08-26
CA2507458A1 (fr) 2004-06-10
JP2010159287A (ja) 2010-07-22
DE60329219D1 (de) 2009-10-22
EP2090566A2 (fr) 2009-08-19
TW200424152A (en) 2004-11-16
BR0316615A (pt) 2005-10-11
EP1567477B1 (fr) 2009-09-09
JP4580240B2 (ja) 2010-11-10
AU2003292112A1 (en) 2004-06-18
US20040132769A1 (en) 2004-07-08
CN1729157A (zh) 2006-02-01
EP1567477A1 (fr) 2005-08-31
JP2006507336A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
US7202364B2 (en) Certain phenylacetic acids and derivatives
US6310099B1 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
KR20060020086A (ko) 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
US8586782B2 (en) Phenylacetic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003767652

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2507458

Country of ref document: CA

Ref document number: 2004554464

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038A7251X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003767652

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316615

Country of ref document: BR